Regulation of Response Regulator Autophosphorylation through Interdomain Contacts*♭*

Christopher M. Barbieri†§, Timothy R. Mack¶‖, Victoria L. Robinson†♭, Matthew T. Miller*♭*, and Ann M. Stock†§¶

From the †Center for Advanced Biotechnology and Medicine, the ¶Graduate School of Biomedical Sciences, and the §Howard Hughes Medical Institute, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, New Jersey 08854-5635 and the *♭Department of Chemistry, Rutgers University, Piscataway, New Jersey 08854-8066

DNA-binding response regulators (RRs) of the OmpR/PhoB subfamily alternate between inactive and active conformational states, with the latter having enhanced DNA-binding affinity. Phosphorylation of an aspartate residue in the receiver domain, usually via phosphotransfer from a cognate histidine kinase, stabilizes the active conformation. Many of the available structures of inactive OmpR/PhoB family proteins exhibit extensive interfaces between the N-terminal receiver and C-terminal DNA-binding domains. These interfaces invariably involve the α4-β5-α5 face of the receiver domain, the locus of the largest differences between inactive and active conformations and the surface that mediates dimerization of receiver domains in the active state. Structures of receiver domain dimers of DrrB, DrrD, and MtrA have been determined, and phosphorylation kinetics were analyzed. Analysis of phosphotransfer from small molecule phosphodonors has revealed large differences in autophosphorylation rates among OmpR/PhoB RRs. RRs with substantial domain interfaces exhibit slow rates of phosphorylation. Rates are greatly increased in isolated receiver domain constructs. Such differences are not observed between autophosphorylation rates of full-length and isolated receiver domains of a RR that lacks interdomain interfaces, and they are not observed in histidine kinase-mediated phosphotransfer. These findings suggest that domain interfaces restrict receiver domain conformational dynamics, stabilizing an inactive conformation that is catalytically incompetent for phosphotransfer from small molecule phosphodonors. Inhibition of phosphotransfer by domain interfaces provides an explanation for the observation that some RRs cannot be phosphorylated by small molecule phosphodonors in vitro and provides a potential mechanism for insulating some RRs from small molecule-mediated phosphorylation in vivo.

A fundamental aspect of signal transduction systems is the ability to toggle between different functional states. Many signaling systems, including two-component systems, utilize protein phosphorylation to modulate their output (1). In two-component systems, the phosphorylation cascade typically proceeds from a histidine kinase (HK)* to the receiver domain of a response regulator (RR) in a reaction catalyzed by the RR (1, 2). Inhibitory or activating interactions with binding partners, specific to the unphosphorylated and/or phosphorylated receiver domains, are the basis of regulatory mechanisms that control RR activity (3).

Receiver domains exist in equilibrium between two predominant conformations designated inactive and active. Although the inactive conformation is energetically favored for unphosphorylated receiver domains and the active conformation is favored for phosphorylated receiver domains, receiver domains sample the active conformation even in the absence of phosphorylation. The coexistence of the two conformations within a population of unphosphorylated RR molecules was demonstrated directly by NMR analysis of Salmonella enterica NtrC (4), and structural and functional characterization of mutant proteins indicated a correlation between transcriptional activity and the position of the equilibrium (4, 5). The studies on NtrC, as well as those on other RRs such as Escherichia coli CheY (6), have been interpreted in terms of a simple two-state model. Although this model is likely an oversimplification of a more complex situation involving multiple functionally relevant conformations (7–10), it provides a useful foundation for understanding the dynamic aspects of RR function.

It is becoming clear that protein dynamics and function are intimately intertwined (11–15). Studies on several different proteins have indicated that enzymatic catalysis or binding activities occur only in subpopulations of proteins that preexist in competent conformations. This phenomenon has been suggested to explain the slow rate of autophosphorylation observed for Mycobacterium tuberculosis MtrA, a RR of the

* This work was supported, in whole or in part, by National Institutes of Health Grant R37GM047958 (to A. M. S.).

† Author’s Choice—Final version full access.

♭ This article was selected as a Paper of the Week.

§ The on-line version of this article (available at http://www.jbc.org) contains supplemental Tables S1 and S2.

The atomic coordinates and structure factors (codes 3NWS, 3NWN, and 3NHZ) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

1 Present address: ImClone Systems Corp., 180 Varick St., New York, NY 10014.

2 Present address: Dept. of Molecular and Cell Biology, University of Connecticut, Storrs, CT 06269-3125.

3 To whom correspondence should be addressed: Center for Advanced Biotechnology and Medicine, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, 679 Hoes Lane, Piscataway, NJ 08854-5627. Tel.: 732-235-4844; Fax: 732-235-5289; E-mail: stock@cabm.rutgers.edu.

4 The abbreviations used are: HK, histidine kinase; RR, response regulator; DBD, DNA-binding domain; BME, β-mercaptoethanol; PA, phosphoramidate.
Domain Contacts Inhibit Response Regulator Phosphorylation

OmpR/PhoB subfamily of RR transcription factors (16). Intracellular or intermolecular interactions of receiver domains have the potential to bias the conformational equilibrium by stabilizing either inactive or active conformations. In unphosphorylated MtrA, the α4–β5–α5 face of the receiver domain forms an interface with the DNA-binding domain (DBD), stabilizing the inactive conformation of the receiver domain. Supporting the hypothesis that the domain interface inhibits autophosphorylation, the isolated MtrA receiver domain, which lacks the constraints of the domain interface, exhibits a much faster rate of autophosphorylation than intact MtrA.

Despite the presence of structurally similar receiver and DBDs, different domain arrangements are observed in all available structures of full-length unphosphorylated (and presumably inactive) OmpR/PhoB subfamily RRs (16–19). When they exist, interdomain interfaces invariably involve the α4–β5–α5 face of the receiver domain interacting with some surface of the DBD. All OmpR/PhoB subfamily RRs are thought to adopt a similar dimeric structure in the active state, with the receiver domains dimerized via conserved residues on the α4–β5–α5 face and tethered to the DBDs by flexible linkers (20–25). Thus, α4–β5–α5 interactions with the DBD in the inactive state are effectively competitive inhibitors of activation. To examine the influences of interdomain interfaces on the catalytic activity of receiver domains, we determined autophosphorylation rates of five OmpR/PhoB subfamily RRs and of their isolated receiver domains. Slow rates of autophosphorylation were found in RRs with domain interfaces, supporting our hypothesis that interactions that stabilize the inactive conformation reduce catalysis. However, this effect was not observed in phototransfer mediated by a cognate HK. The results of this study provide an explanation for reports of some RRs that cannot be phosphorylated by small molecule phosphodonor in vitro and a potential mechanism for limiting phosphorylation by small molecule metabolites in vivo.

EXPERIMENTAL PROCEDURES

Cloning and Molecular Biology—The proteins analyzed in this study were expressed in pJZG92 from a T7 promoter. pJZG92 was created by removing the HindIII/Xhol fragment located within the multiple cloning site of pET21b (Novagen) and replacing it with a synthetically derived oligonucleotide located within the multiple cloning site of pET21b. Genes encoding the different proteins being expressed were introduced into pJZG92—ΔrrdN, ΔrrdDN, ΔrrdD, ΔrrdD N, Δmtra, Δmtra N, ΔprrA, ΔprrA N, ΔphoB, ΔphoB N, and ΔprrB HDCC. Expression in these strains used in this study are listed in supplemental Table S1.

Protein Expression and Purification—DrrD, DrrDN, DrrD, DrrDN, MtrA, Mtra N, PrrA, PrrA N, PhoB, PhoB N, and PrrBHDC were expressed in either E. coli Rosetta(DE3) (PrrB HDC) or BL21(DE3) (all other proteins). All cells were grown at 37 °C to mid-log phase in either Terrific Broth with 1 M sorbitol (PrrA and PrrA N) or LB medium (all other proteins) containing 100 mg/ml ampicillin. Protein expression was induced by the addition of isopropyl 1-thio-β-D-galactopyranoside to a final concentration of 0.5 mM. Following induction, all protein expression strains except those expressing PrrA and PrrA N were grown for an additional 3 h at 37 °C. PrrA and PrrA N were grown for an additional 17 h at 20 °C. Cells were harvested by centrifugation and lysed by sonication Buffer A (20 mM sodium phosphate (pH 7.4), 500 mM NaCl, 25 mM imidazole, and 2 mM β-mercaptoethanol (BME)). The resulting lysate was centrifuged (60,000 × g), filtered through a 0.2-μm filter, and then loaded onto a 1-ml HisTrap™ FF crude column (GE Healthcare) pre-equilibrated with Buffer A. Bound proteins were eluted from the column with a 30-ml linear gradient from Buffer A to 20 mM sodium phosphate (pH 7.4), 500 mM NaCl, 500 mM imidazole, and 2 mM BME at a flow rate of 2 ml/min. Fractions that contained the protein of interest were pooled, filtered using a 0.2-μm filter, and then loaded onto a Superdex 75 26/60 gel filtration column (GE Healthcare) pre-equilibrated with 50 mM Tris (pH 7.5), 500 mM NaCl, and 2 mM BME. The fractions containing pure protein were pooled and stored at −80 °C after rapid freezing in a dry ice/ethanol bath. In some cases, the His6 tag was removed by thrombin treatment, and the digested protein was separated from the undigested protein and the cleaved His6 tag by passing the digested material over a HisTrap™ FF column. Removal of the His6 tag had no effect on subsequent assays. Although His residues can be phosphorylated by phosphoramide (PA), the rates are negligible compared with phosphorylation of RRs at the active-site Asp (26).

Crystallization—Both DrrB N and DrrD N were activated by adding 6 mM BeCl2, 50 mM NaF, and 10 mM MgCl2 to 1.0–1.2 mg/ml protein. The activated proteins were then concentrated to ~15 mg/ml using Amicon Ultra-10 centrifugal filter units (Millipore).

Crystals of activated selenomethionine-derivatized DrrB N were grown using the hanging drop method of vapor diffusion. The protein was mixed with an equal volume of reservoir solution containing 10% 2-propanol, 200 mM Li2SO4, and 0.1 M potassium citrate (pH 4.2). Crystals were cryoprotected by passing them quickly through reservoir solution containing 30% 2-methyl-2,4-pentanediol, 6 mM BeCl2, 50 mM NaF, and 10 mM MgCl2 and then flash-freezing them directly in a 100 K nitrogen stream. The crystals belong to space group C2 with cell constants a = 64.3 Å, b = 37.5 Å, and c = 91.5 Å and β = 108.1°, with two molecules/asymmetric unit.

Crystals of activated DrrD N were grown in a similar manner using reservoir solution composed of 9–12% polyethylene glycol 3350 and 200 mM NaH2PO4. Cryoprotection was done by briefly soaking the crystals in reservoir solution with 20% glycerol, 6 mM BeCl2, 50 mM NaF, and 10 mM MgCl2 and then flash-freezing them directly in a 100 K nitrogen stream. The
crystals belong to space group $P4_12_12$ with cell constants $a = b = 74.9$ and $c = 98.7$ Å, corresponding to two molecules/asymmetric unit.

Crystals of MtrA$_N$ were grown in a similar manner using a reservoir solution composed of $2.6 \text{ M NaCl}, 100 \text{ mM HEPES (pH 7.5)},$ and $100 \text{ mM MgCl}_2$. Crystals formed within 24 h at room temperature and were flash-cooled in liquid nitrogen after being briefly soaked in the reservoir buffer with 25% glycerol. The crystals belong to space group $P2_1$, with cell constants $a = b = 56.6$ and $c = 181.8$ Å, with four molecules/asymmetric unit.

Single-wavelength anomalous dispersion data were collected from a single DrrB$_N$ crystal, and a native data set was collected using a single DrrD$_N$ crystal at beamline X4A at the National Synchrotron Light Source at Brookhaven National Laboratory (Upton, NY). MtrA$_N$ data were collected on a Rigaku MicroMax-007 HF generator equipped with a Rigaku V+ detector. Data were processed and scaled with DENZO and SCALEPACK (27).

Structure Determination and Refinement for DrrB$_N$—Positions of five of the eight selenium sites were determined from the peak wavelength utilizing the single-wavelength anomalous dispersion phasing protocol implemented in CNS with a mean figure of merit of 0.283 and phasing power of 1.24 (28). Initial phase estimates extending to 1.9 Å were improved with solvent flipping and density modification. A starting model was generated utilizing the model building tools in COOT (29). Density modifications were performed with the concentration of RR being small ($10 \mu\text{M}$) relative to $X\sim P$ ($20 \mu\text{M}$) such that plots of the fraction of $[RR\sim P]/[RR\text{total}] (F)$ versus time ($t$) can be fit with a first-order exponential decay of the following form (Equation 1).

$$F = F_0 (1 - e^{k_{\text{obs}}t}) \quad (\text{Eq. 1})$$

In this equation, the values representing the maximum fraction of phosphorylated RR ($F_0$) and observed autophosphorylation rate ($k_{\text{obs}}$) are described by the following equations (Equations 2 and 3).

$$F_0 = k_2/(k_2 - k_3 (1 + 1/(K_a[X\sim P]))) \quad (\text{Eq. 2})$$

$$k_{\text{obs}} = k_3 + (k_2/(1 + 1/(K_a[X\sim P]))) \quad (\text{Eq. 3})$$

Note that both $F_0$ and $k_{\text{obs}}$ are dependent on both the rate of phosphotransfer to the RR ($k_2$) and the RR$\sim P$ hydrolysis rate ($k_3$). The kinetic and equilibrium constants in these equations are covariant parameters preventing an accurate determination of these values using unconstrained nonlinear least-squares analysis of the $F$ versus $t$ plots. Because of this limitation, we have chosen to use $k_{\text{obs}}$ values for the purpose of comparing the autophosphorylation energetics of each RR with its associated receiver domain. This comparison is valid when the concentrations of the reactants are identical in the compared experiments and the autodephosphorylation rates for both the full-length proteins and their isolated receiver domains are equivalent. This assumption is shown to be valid by analysis of the autodephosphorylation rates of two RRs and their receiver domains as herein described.

HPLC—Analyses were performed as described previously (16, 21, 35) using a Hitachi D-7000 HPLC system. Solutions of $10 \mu\text{M}$ protein in 50 mM Tris (pH 7.5), 100 mM NaCl, 2 mM BME, and 10 mM MgCl$_2$ with or without incubations with 20 mM PA were prepared. $30\mu\text{l}$ aliquots were injected onto a C-8 reverse-
Domain Contacts Inhibit Response Regulator Phosphorylation

The rate of RR autodephosphorylation was determined from the slope of the best fit lines for plots of the natural logarithm of the fraction of phosphorylated protein versus time.

**Autophosphorylation of PrrBHDC and Phosphotransfer Analysis**—PrrBHDC-P was prepared by adding 2 mM ATP to a reaction solution containing 20 μM PrrBHDC in 10 mM Tris (pH 8.0), 5 mM MgCl₂, and 50 mM KCl and incubating the solution at 35°C for 90 min, followed by incubation at room temperature for an additional 90 min. This reaction resulted in >50% phosphorylation of PrrBHDC (data not shown). The solution was then cooled to 4°C for subsequent experiments to prevent additional rounds of phosphorylation of PrrBHDC by unreacted ATP and also to slow the phosphotransfer reaction, thereby allowing an accurate rate to be determined without using stopped-flow techniques. Phosphotransfer experiments were initiated by mixing the above solution of ATP-treated PrrBHDC with an equal volume of either 40 μM PrrA or 40 μM PrrAN in the same buffer. PrrBHDC dephosphorylation was monitored by removing and immediately quenching 15-μl aliquots of each reaction solution by the addition of 5 μl of 4× SDS loading buffer at 10, 20, 30, 40, 50, 90, 120, 180, 300, 600, and 1200 s following initiation of the reaction. The extent of protein phosphorylation was determined using phosphoprotein affinity gel electrophoresis, and the rate of PrrBHDC-P-mediated RR phosphorylation was determined from the first-order exponential decay fits for plots of the fraction of PrrBHDC-P versus time.

**RESULTS**

**Structures of DrrBN, DrrDN, and MtrA**—Structures of isolated OmpR/PhoB family receiver domains stabilized in their active conformations either by high protein concentrations or by the presence of the noncovalently associated phosphoryl analog berylliofluoride (37) have been reported previously (20–25, 38). However, no such structures have been determined for RRs for which structures of the inactive full-length proteins are also known. As noted previously, the interdomain interfaces in most inactive OmpR/PhoB RRs determined to date involve the α4-β5-α5 face of the receiver domain, a surface that is also essential for formation of the active-state α4-β5-α5 dimer that is proposed to be common to most all OmpR/PhoB RRs. To explore whether this active-state dimer is adopted by OmpR/PhoB RRs regardless of the involvement of the α4-β5-α5 face of the receiver domain in interdomain interfaces in the inactive state, we determined a set of isolated receiver domain structures for three OmpR/PhoB family proteins for which structures of inactive full-length proteins are available, *T. maritima* DrrB and DrrD and *M. tuberculosis* MtrA (Fig. 1A) (16–18).

The structures of the isolated receiver domains of DrrB, DrrD, and MtrA, henceforth referred to as DrrBN, DrrDN, and MtrAN, respectively, are shown in Fig. 1B. DrrBN and DrrDN were maintained in their activated conformations by the presence of BeF₃⁻, whereas crystals of MtrAN were obtained only in the absence of BeF₃⁻. Clear electron density for BeF₃⁻ is present at the active sites of DrrBN and DrrDN, although the electron density is weaker for DrrDN, suggesting partial occupancy. In these two proteins, the conserved Thr and Tyr switch residues are in orientations characteristic of activated receiver domains, distinct from the orientations observed in the corresponding phase HPLC column (Grace Vydac, Inc.) pre-equilibrated with 31.5% (v/v) acetonitrile and 0.1% (v/v) TFA. Proteins were eluted using a 60-ml gradient from 31.5% (v/v) acetonitrile and 0.1% (v/v) TFA to 58.5% (v/v) acetonitrile and 0.1% (v/v) TFA at a flow rate of 1 ml/min. Absorbance data were recorded at 210, 220, 260, and 280 nm. Areas under each elution peak from the absorbance at 210 nm versus elution time plots were calculated using HPLC-associated software.

**Fluorescence**—Fluorescence experiments were conducted as described previously (36) using a FluoroMax-3 spectrofluorometer (HORIBA Jobin Yvon, Inc., Edison, NJ) equipped with a circulating water bath for temperature control. Fluorescence intensity values (I) corresponding to unphosphorylated protein (I₀) and phosphorylated protein (Iₜ) were determined from the buffer- and dilution-corrected fluorescence intensities at 345 nm taken from the emission spectra of PhoB without PA and after 1800 s of incubation with PA. The fraction of phosphorylated protein at time t was calculated as (Iₜ − I₀)/(Iᵣ − I₀).

**Phosphoprotein Affinity Gel Electrophoresis**—Phos-tag™ acrylamide gels (7 × 8 × 0.075 cm) were prepared as described previously (36). Briefly, Phos-tag™ acrylamide running gels contained 10% (w/v) 29:1 acrylamide/N,N’-methylenebisacrylamide, 375 mM Tris (pH 8.8), and 0.1% (w/v) SDS. Gels were copolymerized with 75 μM Phos-tag™ acrylamide and 150 μM MnCl₂. Stacking gels contained 4% (w/v) 29:1 acrylamide/N,N’-methylenebisacrylamide, 125 mM Tris (pH 6.8), and 0.1% (w/v) SDS. All Phos-tag™ acrylamide-containing gels were run with standard denaturing running buffer (0.4% (w/v) SDS, 25 mM Tris, and 192 mM glycine) at 4°C under constant voltage (160 V). The fraction of phosphorylated protein in each gel lane was determined by monitoring the Coomassie Blue staining intensity for the upshifted (phosphorylated) protein band in each lane relative to the total staining intensity for both bands (total protein) in the lane.

**RR Dephosphorylation Analysis**—His₆-tagged PrrA, PrrAN, DrrB, and DrrBN were each phosphorylated by PA as follows. 750-μl solutions of 12 μM PrrA, 60 μM PrrAN, 15 μM DrrB, or 15 μM DrrBN were prepared in reaction buffer (50 mM Tris (pH 7.5), 100 mM NaCl, 2 mM BME, and 10 mM MgCl₂) containing either 20 mM PA (PrrAN experiments) or 60 mM PA (all other experiments). PrrA, PrrAN, and DrrBN solutions were incubated at room temperature for 45 min, and DrrB was incubated at 60°C for 20 min and at room temperature for 5 min. 150 μl (PrrAN) or 50 μl (all other proteins) of nickel-nitroliotriatic acid-agarose beads (Qiagen) were added to the reaction solution. After 10 min to allow all proteins to bind to the beads, the samples were centrifuged at 2000 × g for 1 min to pellet the beads, and the supernatant was removed. The samples were washed three times with reaction buffer, with the beads being centrifuged and the supernatant removed each time. Samples were eluted from the beads using 333 mM imidazole, 33 mM Tris (pH 7.5), 67 mM NaCl, and 6.7 mM MgCl₂. Samples were diluted 1:3 in reaction buffer. To monitor the extent of protein phosphorylation, 15-μl aliquots from each reaction solution were quenched at 10–15-min intervals by the addition of 5 μl of 4× SDS loading buffer. The extent of protein phosphorylation was determined using phosphoprotein affinity gel electrophoresis.
The highly conserved salt bridges are substituted by a Val-Ile pair that expands the hydrophobic contact at the domain interface (Fig. 2A and B). Additional contacts unique to MtrAN and YycF are observed in the presence of the phosphoryl analog BeF3. The absence of an interdomain interface has not been observed in any other crystal structures of inactive OmpR/PhoB RRs, likely reflecting a bias in the structural data obtained in the presence of the phosphoryl analogs (22, 24). It seems likely that reorientation of the conserved Tyr side chain toward the protein interior upon phosphorylation would allow both MtrA and YycF to adopt the same α4-β5-α5 dimer interface and ionic interaction network of conserved charged residues that typify most other OmpR/PhoB RR active dimers.

The previously determined structures of inactive full-length DrrB, DrrD, and MtrA reveal remarkably different interdomain interfaces between the receiver and DNA-binding domains. Despite its short interdomain linker, DrrD has an interdomain interface of only 250 Å² (17), much less than the minimum surface area expected for a physiologically relevant stable protein interface (39). The absence of an interdomain interface has not been observed in any other crystal structures of inactive OmpR/PhoB RRs, likely reflecting a bias in the structural data base toward proteins most amenable to crystallization. In contrast, both DrrB and MtrA display tightly packed interfaces that bury 750 and 720 Å², respectively (16, 18), similar to interfaces in most other structurally characterized OmpR/PhoB family RRs (19).

Many of the residues involved in contacts between pro-ADP-ribosyltransferase of the DrrBN and MtrAN dimers characterized in this study (Fig. 1B) are also involved in contacts between the N- and C-terminal domains in the inactive full-length proteins (16, 18). Thus, substantial rearrangements of the domains must occur in transitions between inactive and active states. Furthermore, in both proteins, the inactive conformation is stabilized by an interdomain hydrogen bond that involves the conserved Tyr residue in the receiver domain (Tyr102 in MtrAN and Tyr98 in YycFN) that project toward proteins most amenable to crystallization. In contrast, both DrrB and MtrA display tightly packed interfaces that bury 750 and 720 Å², respectively (16, 18), similar to interfaces in most other structurally characterized OmpR/PhoB family RRs (19).

Unlike inactive DrrB, inactive DrrD contains few intramolecular interactions that would prevent the receiver domain from obtaining an active conformation. The orientations of the conserved Thr81 and Tyr100 residues in the receiver domain of full-length DrrD are different from those in the structure of BeF3-activated DrrD, but deviate from the orientations of switch residues observed in most other inactive receiver domains. Although the intermediate orientations of the switch residues are possibly influenced by packing interactions in the crystal lattice, they provide evidence for the plasticity of the inactive receiver domain when unconstrained by interdomain contacts.
Determination of Protein Autophosphorylation Rates—To assess the influence of interdomain interfaces on the propensity for phosphorylation, the extent and rate of phosphotransfer from the small molecule phosphodonor PA to structurally characterized OmpR/PhoB RRs were determined. Multiple previously documented techniques for monitoring RR phosphorylation (34–36) were employed because of the large variation in autophosphorylation rates among RRs, requiring seconds to hours to achieve steady-state levels. Autophosphorylation of *T. maritima* DrrB and DrrD, RRs with very different interdomain interfaces, was characterized using Phos-tag™ acrylamide gel electrophoresis. The extent of autophosphorylation for DrrB, DrrD, and the corresponding isolated receiver domains (DrrBN and DrrDN) is shown in Fig. 3. DrrB remained nearly completely unphosphorylated even after 20 min of treatment with PA as evidenced by the absence of an upshifted band in the Phos-tag™ gels in Fig. 3A. Conversely, DrrD became nearly completely phosphorylated under these conditions as evidenced by the disappearance of the lower band and the appearance of the upper band in the gels depicted in Fig. 3B. Both DrrBN and DrrDN autophosphorylated readily, reaching nearly complete phosphorylation in 10 and 20 min, respectively, following the addition of PA (Fig. 3, A and B). The slow rate of phosphorylation of DrrB relative to that of DrrBN in contrast to the similar rates of phosphorylation for DrrD and DrrDN is consistent with the hypothesis that interdomain interactions inhibit autophosphorylation. This inhibition is relieved in isolated receiver domains and in full-length RRs that lack substantial interdomain interfaces.

Analysis of autophosphorylation was performed on additional RRs. Autophosphorylation rates in the presence of PA were determined by plotting the extent of RR phosphorylation as a function of time and fitting with a single exponential decay, yielding an observed rate of autophosphorylation ($k_{\text{obs}}$) as described under “Experimental Procedures” (for representative plots, see Fig. 3, C and D). The $k_{\text{obs}}$ value provides a useful numerical method for comparing the autophosphorylation rates of RRs with those of their isolated receiver domains and also with each other. Table 1 lists the observed autophosphorylation rates for DrrB, DrrD, MtrA, PrrA, and PhoB and for their isolated receiver domains. The ratio of the $k_{\text{obs}}$ values for the receiver domain versus the full-length form of each RR facilitates comparison of the different RRs. The full-length forms of MtrA and PrrA, like DrrB, have low rates of phosphorylation. It is notable that these three proteins all have extensive interdomain interfaces, and in each of these slowly phosphorylating
proteins, removal of the DBD enhances the autophosphorylation rate by >9-fold.

DrrD, which lacks an extensive interface, phosphorylates readily in both full-length and truncated forms. PhoB, for which the structure has not been determined, exhibits similar phosphorylation behavior. The similarity in phosphorylation kinetics for full-length PhoB and the isolated receiver domain suggests that PhoB might lack an extensive domain interface. Further support for a weak interdomain interface has been obtained from NMR analyses. The transverse relaxation optimized spectroscopy-heteronuclear single quantum coherence spectrum of inactive full-length PhoB superimposes almost exactly with the combined spectra of the isolated receiver and DNA-binding domains, suggesting that there are no extensive interactions between the two domains (40).

Although misfolding of full-length RRs is a possible explanation for the low autophosphorylation activity of DrrB, MtrA, and PrrA, several observations argue against this. All of the proteins behave homogeneously during purification, with no evidence of aggregation. Furthermore, concentrated solutions of these proteins readily yield crystals of native protein under appropriate crystallization conditions. Importantly, the low stoichiometry of phosphorylation at steady state can be increased to >50% by manipulating the reaction conditions, either by increasing the reaction temperature or by increasing the concentration of PA in the reaction (see below). The latter observation is consistent with previous studies showing that RR phosphorylation is linearly dependent on phosphodonor concentration because of the very low affinity of RRs for small molecule phosphodonor (41). Thus, the low stoichiometries of phosphorylation observed under the experimental conditions in this study do not result from limiting quantities of native protein available for phosphorylation but rather reflect low rates of phosphorylation relative to the rates of dephosphorylation.

Influence of the DBD on Autodephosphorylation Rate—Removal of the DBD enhances the observed rate of autophosphorylation for three of the five RRs examined. However, it is possible that this effect results from altered rates of dephosphorylation of the RR receiver domain because the $k_{\text{obs}}$ value is dependent on both the rate of phosphotransfer from PA and the rate of dephosphorylation of the RR. To address the contributions of these two opposing rates, dephosphorylation rates ($k_{\text{dephos}}$) were measured for PrrA and DrrB, two of the RRs that have increased $k_{\text{obs}}$ values when the DBD is removed (Fig. 4). Both full-length proteins and their isolated receiver domains were phosphorylated with PA. To enhance the extent of phosphorylation of the full-length proteins to >50%, either the PA concentration was increased (for PrrA) or the incubation temperature was raised (for DrrB). After removing unreacted PA by affinity chromatography, the rate of dephosphorylation of each protein was measured using phosphoprotein affinity gel electrophoresis.

### TABLE 1

| Protein | Domain interface | $k_{\text{obs}}$ | $k_{\text{obs}}^N/k_{\text{obs}}^\text{Full}$ | $k_{\text{dephos}}$ | Technique |
|---------|-----------------|-----------------|---------------------|-------------------|-----------|
| DrrB    |                | 750             | >100                | 0.09 ± 0.01       | HPLC      |
| DrrB$_N$|                | <0.01           |                     |                   | Phos-tag$^\text{TM}$ |
| DrrD    |                | 250             | 0.7                 | 0.09 ± 0.01       | Phos-tag$^\text{TM}$ |
| DrrD$_N$|                | 0.07 ± 0.01     |                     |                   | Phos-tag$^\text{TM}$ |
| PhoB    | Unknown         | 0.45 ± 0.01     | 1.0                 |                   | Fluorescence |
| PhoB$_N$|                | 0.44 ± 0.01     |                     |                   | Fluorescence |
| MtrA    | PhoBN$_N$      | 0.014 ± 0.005   | 10.7                |                   | $^{32}$P incorporation |
| MtrA$_N$|                | 0.15 ± 0.02     |                     | 0.04 ± 0.01       | HPLC      |
| PrrA    | PhoBN$_N$      | 0.028 ± 0.010   | 9.2                 | 0.06 ± 0.01       | HPLC      |
| PrrA$_N$|                | 0.26 ± 0.01     |                     |                   | HPLC      |

$a$ The interdomain interface areas were calculated using AREAIMOL in the CCP4 suite (62).

$b$ The ratio of $k_{\text{obs}}$ for the isolated N-terminal domain ($k_{\text{obs}}^N$) versus $k_{\text{obs}}$ for the full-length RR ($k_{\text{obs}}^\text{Full}$) was used to compare the effects of domain interactions on RR autophosphorylation between different proteins.

c The various techniques used for determining the rates of autophosphorylation for RR proteins are indicated as follows: HPLC, Phos-tag$^\text{TM}$ (phosphoprotein affinity gel electrophoresis), fluorescence (phosphorylation-induced changes in intrinsic tryptophan fluorescence), and $^{32}$P incorporation (radiometric analysis of $^{32}$P phosphotransfer from [S$^{32}$P]phosphoramidate). Descriptions of these techniques are given under "Experimental Procedures." $d$ Previously reported data for autophosphorylation of MtrA (16) were quantitated as described under "Experimental Procedures" (Equation 1).
Domain Contacts Inhibit Response Regulator Phosphorylation

![Graph showing the rate of phosphotransfer from PrrB_HDC to PrrA and PrrAN.](image)

**FIGURE 5. Rate of phosphotransfer from PrrB_HDC to PrrA and PrrAN.**

*Showed is a plot of the fraction of phosphorylated PrrBHDC observed at various time points following incubation with PrrA (●) or PrrAN (○). Solid and dashed lines depict the first-order exponential decay fits using PrrA and PrrAN as the phosphoacceptors, respectively. Each data point represents the average of at least two independent experiments, with error bars representing S.D.*

...trophoerosis following quenching of the autodephosphorylation reaction by denaturation with SDS. The $k_{\text{dephos}}$ values listed in Table 1 demonstrate that, for PrrA and DrrB, the presence of DBD does not significantly alter $k_{\text{dephos}}$, confirming that the differences in $k_{\text{obs}}$ between full-length RRs and isolated receiver domains reflect an effect on autophosphorylation rates rather than dephosphorylation rates.

**PrrB-mediated Phosphotransfer to PrrA—**Small molecule phosphodonsors such as acetyl phosphate are thought to be minor contributors to the overall phosphorylation state of most RRs within cells (42–45). The major route of RR phosphorylation is through phosphotransfer from cognate HKs. To determine whether the inhibitory effects of interdomain interactions on receiver domain autophosphorylation by small molecule phosphodonsors are also applicable to HK-mediated RR phosphorylation, phosphotransfer from the cytoplasmic domain of PrrB (PrrB_HDC), the cognate HK of PrrA, to full-length PrrA and PrrAN was characterized. Phosphotransfer from phosphorylated PrrB_HDC to the PrrA proteins was assayed by measuring the decrease in the fraction of phosphorylated PrrB_HDC, as shown in Fig. 5. The studies were performed at 4°C to ensure that the phosphotransfer rate was in the appropriate time scale for measurement using available techniques. The $k_{\text{obs}}$ value for PrrA phosphorylation via PrrB was 0.011 ± 0.001 min$^{-1}$, whereas that for PrrAN phosphorylation was 0.008 ± 0.001 min$^{-1}$. These values are nearly within the experimental error, demonstrating that, unlike the case with small molecule phosphodonsors, interdomain interactions do not inhibit RR phosphorylation via a cognate HK.

**DISCUSSION**

**Interactions That Alter RR Protein Dynamics Modulate Autophosphorylation—**Substantial differences in rates of autophosphorylation occur among the different RRs characterized in this study. To a first approximation, the OmpR/PhoB RRs can be grouped into two distinct classes based on observed autophosphorylation rates: 1) RRs that are readily phosphorylatable (e.g. DrrD and PhoB) and 2) RRs that are poorly phosphorylatable (e.g. DrrB, MtrA, and PrrA). Interestingly, these groupings correlate with an obvious feature of the structurally characterized RRs (DrrD, DrrB, MtrA, and PrrA), specifically the extent of the interdomain interface of the proteins in their inactive states. Proteins that phosphorylate poorly have substantial interdomain interfaces. It should be noted that the class of RRs that are readily phosphorylable contains only one structurally characterized RR, likely reflecting the difficulty of crystallizing proteins with multiple domains that lack fixed orientations. However, the additional finding that removal of the DBD significantly enhances the rate of autophosphorylation for the poorly phosphorylatable RRs with extensive interdomain interfaces but not for the readily phosphorylable RRs that lack substantial interfaces strongly suggests that interdomain interactions inhibit autophosphorylation.

Despite the observation that RRs with substantial interdomain interactions have diminished rates and extents of phosphorylation, structural models show few direct contacts between residues at the domain interface and the catalytic residues required for phosphorylation (16, 18, 19). It seems likely that the interdomain interactions observed in the poorly phosphorylatable RRs stabilize a conformation that is not catalytically competent, whereas RRs with weak interdomain interactions, like isolated receiver domains, have fewer conformational constraints preventing adoption of a phosphorylatable conformation.

Unphosphorylated receiver domains have been shown to exist in a concentration-independent equilibrium between at least two distinct conformational states, with the minor population resembling that of the phosphorylated form and designated the active conformation (4, 5, 7, 15, 46, 47). Our data are consistent with the hypothesis that catalysis of phosphorylation by small molecule phosphodonsors occurs in a subpopulation of the unphosphorylated receiver domains that pre-exist in an active conformation. This hypothesis has precedent in the conclusions reached by Kern and co-workers (11) in their studies of the prolyl cis,trans-isomerase cyclophilin A. Using NMR relaxation techniques (48), they correlated conformational dynamics with enzyme activity and concluded that catalysis occurs only within a minor subpopulation of the cyclophilin A molecules that pre-exist in a catalytically competent conformation, analogous to the substrate-bound form. Our study of OmpR/PhoB RRs provides another example in which conformational rearrangements appear to be the rate-limiting step in catalysis.

The schematic reaction diagram depicted in Fig. 6 links the conformational energetics of RR proteins to their ability to undergo autophosphorylation by small molecule phosphodonsors. In this model, the rearrangement into a phosphorylatable conformation is a major energetic barrier to the phosphorylation reaction. The extent of this barrier to phosphorylation can be modulated by RR interdomain interactions. To adopt a phosphorylatable conformation, RRs with more extensive interfaces have a greater energetic barrier to overcome than RRs with less extensive interdomain interfaces. Thus, RRs with more extensive interfaces have a lower initial free energy. This initial free energy defines the magnitude of the phosphorylation activation free energy ($\Delta G^\ddagger$) if the high energy transition state (Fig. 6, *starburst*) is assumed to be similar for all RRs regardless of their initial steady-state conformation (Fig. 6, *oval*).

Although this study has focused on interdomain interactions that stabilize the inactive conformation of receiver domains,
Domain Contacts Inhibit Response Regulator Phosphorylation

Manipulation of Conformational Equilibria Can Be a Useful Tool for Biochemical and Structural Studies—It has been described here and observed elsewhere, although often unpublished, that some RRs are not readily phosphorylated using small molecule phosphodonor molecules. In some cases, deviations in conserved active-site residues clearly indicate that the RRs have evolved to function independently of phosphorylation (50–53). However, in other cases in which active sites are retained, the inability to be phosphorylated by small molecule phosphodonor molecules has possibly been misinterpreted to suggest that phosphorylation is not an essential signaling mechanism for these proteins. In these RRs, the inhibitory effects of interdomain interactions provide an alternative explanation for the absence of observable autophosphorylation.

Our analysis of PrrA demonstrates that the inhibitory effects of interdomain interfaces do not impact phosphotransfer from the cognate HK to the RR. Thus, analysis of phosphorylation in vitro using HK-RR pairs is presumably a robust method for assessing the potential for RR phosphorylation. However, in some cases, the cognate HK is unknown, or the transmembrane HK or suitable soluble domains cannot be purified in a functional state. In such cases, if RRs are found not to be phosphorylatable by small molecule phosphodonor, removal of the effector domain of the RR might provide a simple method for verifying whether the receiver domain is capable of phosphorylation.

It is apparent from the available structures of full-length RRs that domains are arranged differently in different RRs even among RRs of a single subfamily with similar domain architectures. Knowledge of domain arrangements is important to understanding function because distinct inhibitory or activating protein-protein interactions specific to the inactive or active states enable different regulatory strategies (54). Unfortunately, structures of full-length RRs are few compared with those of isolated RR domains. Additionally, these structures are biased toward proteins amenable to crystallization, likely favoring those with interdomain interfaces over those with domains connected by flexible linkers. The observed correlation between reduced autophosphorylation rates of full-length RRs relative to isolated receiver domains and the presence of interdomain interfaces suggests that autophosphorylation kinetics might provide a simple biochemical method for inferring the strength of interdomain interfaces involving receiver domains in individual RRs.

Roles for Interactions That Influence the Conformational Dynamics of RRs—Interdomain interfaces involving receiver domains can potentially influence RR activity in many different ways. Interfaces in inactive RRs that sterically block access to functional regions of effector domains, such as the recognition helices of transcription factors, ensure a very low level of basal activity in the unphosphorylated protein. In inactive RRs of the OmpR/PhoB family, interfaces with effector domains involve the α4-β5-α5 face of the receiver domain, making the effector domain essentially a competitive inhibitor of the active-state dimer. This study has demonstrated yet another way that interdomain interfaces can pose a barrier to RR activation, specifically by restricting the conformational dynamics required for phosphorylation by small molecule phosphodonor.

The inhibition of catalysis by interdomain interfaces is specific to autophosphorylation and does not occur during phosphotransfer between HK-RR pairs, at least in the case of phosphotransfer from PrrB to PrrA. This difference has several possible origins that individually or in combination might account for the different effects of interdomain interfaces on these interactions are not the sole regulatory mechanisms for modulating the activation energy for RR autophosphorylation. Any intra- or intermolecular interactions that stabilize or destabilize one of the conformational states of the receiver domain and thus alter the population distribution of the active and inactive substates of the protein would be expected to alter the rate of RR autophosphorylation. Indeed, autophosphorylation of OmpR has been shown to increase in the presence of oligonucleotides that contain OmpR recognition sequences (49). Our own analyses of this transcription factor concur with these findings and further show that the autophosphorylation rate of DNA-bound OmpR is faster than that of not only OmpR alone but also than that of the isolated receiver domain of OmpR. These observations are consistent with the notion that DNA binding stabilizes the active conformation, biasing the conformational equilibrium and increasing the population of OmpR molecules that exist in a catalytically competent state.

These findings provide examples of domain interactions that influence enzymatic reactions through their modulation of protein dynamics. The inhibitory and activating domain interactions described are not likely restricted solely to the proteins studied here and are expected to occur broadly throughout the entire family of RR proteins as well as in other enzymes. The interplay of inhibitory and activating intra- and intermolecular domain interactions might be an important strategy contributing to the regulation of signaling activities of RR proteins.

It is apparent from the available structures of full-length RRs that domains are arranged differently in different RRs even among RRs of a single subfamily with similar domain architectures. Knowledge of domain arrangements is important to understanding function because distinct inhibitory or activating protein-protein interactions specific to the inactive or active states enable different regulatory strategies (54). Unfortunately, structures of full-length RRs are few compared with those of isolated RR domains. Additionally, these structures are biased toward proteins amenable to crystallization, likely favoring those with interdomain interfaces over those with domains connected by flexible linkers. The observed correlation between reduced autophosphorylation rates of full-length RRs relative to isolated receiver domains and the presence of interdomain interfaces suggests that autophosphorylation kinetics might provide a simple biochemical method for inferring the strength of interdomain interfaces involving receiver domains in individual RRs.

Roles for Interactions That Influence the Conformational Dynamics of RRs—Interdomain interfaces involving receiver domains can potentially influence RR activity in many different ways. Interfaces in inactive RRs that sterically block access to functional regions of effector domains, such as the recognition helices of transcription factors, ensure a very low level of basal activity in the unphosphorylated protein. In inactive RRs of the OmpR/PhoB family, interfaces with effector domains involve the α4-β5-α5 face of the receiver domain, making the effector domain essentially a competitive inhibitor of the active-state dimer. This study has demonstrated yet another way that interdomain interfaces can pose a barrier to RR activation, specifically by restricting the conformational dynamics required for phosphorylation by small molecule phosphodonor.

The inhibition of catalysis by interdomain interfaces is specific to autophosphorylation and does not occur during phosphotransfer between HK-RR pairs, at least in the case of phosphotransfer from PrrB to PrrA. This difference has several possible origins that individually or in combination might account for the different effects of interdomain interfaces on...
small molecule- and HK-mediated phosphorylation of RRs. Phosphotransfer occurs within an HK-RR complex, and interactions between the HK and RR might stabilize a catalytically competent conformation of the receiver domain. Indeed, in the recently reported structure of a *T. maritima* HK-RR complex, the receiver domain adopts an active conformation despite the absence of phosphorylation or a phosphoryl mimic (55). Also, within the HK-RR complex, both proteins contribute residues to the active site of phosphotransfer, and it is possible that the catalytic mechanism and/or transition state differs between autophosphorylation and phosphotransfer reactions. However, kinetic analyses suggest that the approximately thousandfold greater rate observed for HK-mediated relative to small molecule-mediated phosphorylation of RRs can be explained primarily by the productive docking of the phosphoryl substrate in the RR active site that occurs upon HK-RR interaction without invoking a different catalytic mechanism (41). In this context, our data suggest that interdomain interfaces influence substrate binding, a step that is rate-limiting for phosphorylation from small molecule phosphodonors but not for phosphotransfer from phosphohistidine residues within HK-RR complexes. This interpretation coincides with the emerging view that ligands or substrates bind to distinct conformational isomers that pre-exist within conformationally diverse populations. This conformational selection model is gaining favor over both the lock-and-key and induced-fit models of protein-ligand interactions (for reviews, see Refs. 56–58).

Although phosphotransfer from cognate HKs is the primary mechanism for phosphorylation of most RRs in *vivo*, phosphorylation by acetyl phosphate is thought to contribute to the regulation of some RRs (for review, see Ref. 45). Intracellular levels of acetyl phosphate vary greatly under different growth conditions, with concentrations in *E. coli* estimated to range from 0.01 to ~3 mM, the latter being sufficiently high to enable RR autophosphorylation (44, 59). Acetyl phosphate has been shown to regulate the activities of several RRs in the absence of RR phosphatase activity of cognate HKs, and it has been postulated that in, the presence of HKs, acetyl phosphate might contribute to basal phosphorylation of some RRs, altering the sensitivity of the response (44). Furthermore, acetyl phosphate has been shown to be an important regulator of a few specific two-component systems, presumably functioning through direct phosphorylation of RRs (60, 61). Thus, interdomain interfaces that inhibit autophosphorylation have the potential to serve a physiological role, providing a mechanism to maintain signal specificity in two-component systems by insulating some RRs from activation by small molecule phosphodonors.

### Acknowledgments
We thank Ti Wu for assistance with protein purification and the staff at beamlines 4A4 and 4C4 at the National Synchrotron Light Source at Brookhaven National Laboratory for assistance with x-ray diffraction data collection.

### References
1. Hoch, J. A., and Silhavy, T. J. (eds) (1995) *Two-component Signal Transduction*, American Society for Microbiology Press, Washington, DC.
2. Stock, A. M., Robinson, V. L., and Goudreau, P. N. (2000) *Ann. Rev. Biochem.*, 69, 183–215.
3. Gao, R., Mack, T. R., and Stock, A. M. (2007) *Trends Biochem. Sci.*, 32, 225–234.
4. Volkman, B. F., Lipson, D., Wemmer, D. E., and Kern, D. (2001) *Science*, 291, 2429–2433.
5. Nohalie, M., Kern, D., Wemmer, D., Stedman, K., and Kustu, S. (1997) *J. Mol. Biol.*, 273, 299–316.
6. Schuster, M., Silversmith, R. E., and Bouret, R. B. (2001) *Proc. Natl. Acad. Sci. U.S.A.*, 98, 6003–6008.
7. Simonovic, M., and Volz, K. (2001) *J. Biol. Chem.*, 276, 28637–28640.
8. Da Re, S., Tolstyk, T., Wolanin, P. M., and Stock, J. B. (2002) *Protein Sci.*, 11, 2644–2654.
9. Guhaniyogi, J., Robinson, V. L., and Stock, A. M. (2006) *J. Mol. Biol.*, 359, 624–645.
10. Dyer, C. M., and Dahlquist, F. W. (2006) *J. Bacteriol.*, 188, 7354–7363.
11. Eisenmesser, E. Z., Millet, O., Labeikovsky, W., Kozhnev, D. M., Wolf-Watz, M., Bosco, D. A., Skalicek, J. J., Kay, L. E., and Kern, D. (2005) *Nature*, 438, 117–121.
12. Henzler-Wildman, K., and Kern, D. (2007) *Nature*, 450, 964–972.
13. Henzler-Wildman, K. A., Lei, M., Thai, V., Kerns, S. J., Karplus, M., and Kern, D. (2007) *Nature*, 450, 913–916.
14. Henzler-Wildman, K. A., Thai, V., Lei, M., Ott, M., Wolf-Watz, M., Fenn, T., Pozharski, E., Wilson, M. A., Petsko, G. A., Karplus, M., Huber, C. G., and Kern, D. (2007) *Nature*, 450, 838–844.
15. Gardino, A. K., Villali, J., Kivenson, A. L., Lei, M., Liu, C. F., Steindel, P., Eisenmesser, E. Z., Labeikovsky, W., Wolf-Watz, M., Clarkson, M. W., and Kern, D. (2009) *Cell*, 139, 1109–1118.
16. Friedland, N., Mack, T. R., Yu, M., Hung, L. W., Terwilliger, T. C., Waldo, G. S., and Stock, A. M. (2007) *Biochemistry*, 46, 6733–6743.
17. Buckler, D. R., Zhou, Y., and Stock, A. M. (2002) *Structure*, 10, 153–164.
18. Robinson, V. L., Wu, T., and Stock, A. M. (2003) *J. Bacteriol.*, 185, 4186–4194.
19. Nowak, E., Panijkar, S., Konarev, P., Svergun, D. I., and Tucker, P. A. (2006) *J. Biol. Chem.*, 281, 9659–9666.
20. Bent, C. J., Isacs, N. W., Mitchell, T. J., and Riboldi-Tunnicliffe, A. (2004) *J. Bacteriol.*, 186, 2872–2879.
21. Toro-Roman, A., Mack, T. R., and Stock, A. M. (2005) *J. Mol. Biol.*, 349, 11–26.
22. Toro-Roman, A., Wu, T., and Stock, A. M. (2005) *Protein Sci.*, 14, 3077–3088.
23. Bachhawat, P., Swapna, G. V., Montelione, G. T., and Stock, A. M. (2005) *Structure*, 13, 1353–1363.
24. Bachhawat, P., and Stock, A. M. (2007) *J. Bacteriol.*, 189, 5987–5995.
25. Hong, E., Lee, H. M., Ko, H., Kim, D. U., Jeon, B. Y., Shin, J., Lee, S. A., Kim, Y., Jeon, Y. H., Cheong, C., Cho, H. S., and Lee, W. (2007) *J. Biol. Chem.*, 282, 20667–20675.
26. Buckler, D. R., and Stock, A. M. (2000) *Anal. Biochem.*, 283, 222–227.
27. Otwinowski, Z., andMinor, W. (1997) *Methods Enzymol.*, 286, 307–326.
28. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, I. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonov, T., and Warren, G. L. (1998) *Acta Crystallogr. D Biol. Crystallogr.*, 54, 905–921.
29. Emsley, P., and Cowtan, K. (2004) *Acta Crystallogr. D Biol. Crystallogr.*, 60, 2126–2132.
30. Laskowski, R. A., McArthur, M. W., Moss, D. S., and Thornton, J. M. (1993) *J. Appl. Crystallogr.*, 26, 282–291.
31. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) *J. Appl. Crystallogr.*, 40, 658–674.
32. Adams, P. D., Gopal, K., Grosse-Kunstleve, R. W., Hung, L. W., Loeger, T. R., McCoy, A. J., Moriarty, N. W., Pai, R. K., Read, R. I., Rome, T. D., Sacchettini, J. C., Sauter, N. K., Storoni, L. C., and Terwilliger, T. C. (2004) *J. Synchrotron Radiat.*, 11, 53–55.
33. Davis, I. W., Leveray-Fay, A., Chen, Y. V., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., 3rd, Snoeyink, J., Richardson, J. S., and Richardson, D. C. (2007) *Nucleic Acids Res.*, 35, W375–W383.
34. Lukat, G. S., McCleary, W. R., Stock, A. M., and Stock, J. B. (1992) *Proc. Natl. Acad. Sci. U.S.A.*, 89, 718–722.
35. Head, C. G., Tardy, A., and Kenney, L. J. (1998) *J. Mol. Biol.*, 281, 857–870.

32334 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285 • NUMBER 42 • OCTOBER 15, 2010
Domain Contacts Inhibit Response Regulator Phosphorylation

OCTOBER 15, 2010 • VOLUME 285 • NUMBER 42
JOURNAL OF BIOLOGICAL CHEMISTRY 32335

36. Barbieri, C. M., and Stock, A. M. (2008) Anal. Biochem. 376, 73–82
37. Wemmer, D. E., and Kern, D. (2005) J. Bacteriol. 187, 8229–8230
38. Zhao, H., Heroux, A., Sequeira, R. D., and Tang, L. (2009) Acta Crystallogr. D Biol. Crystallogr. 65, 719–722
39. Jones, S., Marin, A., and Thornton, J. M. (2000) Protein Eng. 13, 77–82
40. Bachhawat, P. (2005) Regulation in the OmpR/PhoB Family of Response Regulators: Different Inactive States Lead to a Common Active State. Ph.D. dissertation, University of Medicine and Dentistry of New Jersey Graduate School of Biomedical Sciences, Piscataway, NJ
41. Da Re, S. S., Deville-Bonne, D., Tolstykh, T., Véron, M., and Stock, J. B. (1999) FEBS Lett. 457, 323–326
42. McCleary, W. R., Stock, J. B., and Ninfa, A. J. (1993) J. Bacteriol. 175, 2793–2798
43. Wanner, B. L. (1993) J. Cell. Biochem. 51, 47–54
44. McCleary, W. R., and Stock, J. B. (1994) J. Biol. Chem. 269, 31567–31572
45. Wolfe, A. J. (2005) Microbiol. Mol. Biol. Rev. 69, 12–50
46. Kern, D., Volkman, B. F., Luginbuhl, P., Nohaile, M. J., Kustu, S., and Wemmer, D. E. (1999) Nature 40, 894–898
47. Gardino, A. K., Volkman, B. F., Cho, H. S., Lee, S. Y., Wemmer, D. E., and Kern, D. (2003) J. Mol. Biol. 331, 245–254
48. Gardino, A. K., and Kern, D. (2007) Methods Enzymol. 423, 149–165
49. Ames, S. K., Frankema, N., and Kenney, L. J. (1999) Proc. Natl. Acad. Sci. U.S.A. 96, 11792–11797
50. Schär, J., Sickmann, A., and Beier, D. (2005) J. Bacteriol. 187, 3100–3109
51. Fraser, J. S., Merlie, J. P., Jr., Echols, N., Weisfield, S. R., Mignot, T., Wemmer, D. E., Zusman, D. R., and Alber, T. (2007) Mol. Microbiol. 65, 319–332
52. Ruiz, D., Salinas, P., Lopez-Redondo, M. L., Cayuela, M. L., Marina, A., and Contreras, A. (2008) Microbiology 154, 3002–3015
53. Kato, H., Chibazakura, T., and Yoshikawa, H. (2008) Biosci. Biotechnol. Biochem. 72, 1072–1079
54. Gao, R., and Stock, A. M. (2010) Curr. Opin. Microbiol. 13, 160–167
55. Casino, P., Rubio, V., and Marina, A. (2009) Cell 139, 325–336
56. James, L. C., and Tawfik, D. S. (2003) Trends Biochem. Sci. 28, 361–368
57. Benkovic, S. J., and Hammes-Schiffer, S. (2003) Science 301, 1196–1202
58. Boehr, D. D., Nussinov, R., and Wright, P. E. (2009) Nat. Chem. Biol. 5, 789–796
59. Klein, A. H., Shulla, A., Reimann, S. A., Keating, D. H., and Wolfe, A. J. (2007) J. Bacteriol. 189, 5574–5581
60. Bouché, S., Klauck, E., Fischer, D., Lucassen, M., Jung, K., and Hengge-Aronis, R. (1998) Mol. Microbiol. 27, 787–795
61. Fredericks, C. E., Shibata, S., Aizawa, S., Reimann, S. A., and Wolfe, A. J. (2006) Mol. Microbiol. 61, 734–747
62. Collaborative Computational Project (1994) Acta Crystallogr. D Biol. Crystallogr. 50, 760–763